US TB Cases Rise Post-Pandemic, World's Deadliest Infection Resurges

Tuberculosis (TB), a highly contagious bacterial infection historically known as the 'White Plague', is experiencing a significant resurgence in the United States, reversing nearly three decades of declining incidence. This alarming trend has prompted health officials to raise concerns, particularly as TB has regained its status as the world's deadliest infectious disease. For many years, the United States had witnessed a steady decrease in TB cases following the advent of antibiotics in the 1950s and significant public health efforts. This led to hopes of eradication, with the US committing to a goal of less than 1 case per 1,000,000 population in 1989. However, this progress has been significantly set back in recent years. According to data from the Centers for Disease Control and Prevention (CDC), TB cases in the US increased from 2021 through 2024. In 2023, the US provisionally reported 9,633 TB cases, marking a 15.6% increase compared to 2022 and the highest count since 2013. This figure also surpassed pre-pandemic levels from 2019. Provisional data for 2024 showed a further rise to 10,388 cases, an 8% increase from 2023, representing the highest number of cases since 2011. While provisional data for 2025 indicates a slight decrease to 10,260 cases, a 1% decline from 2024, the overall trajectory since 2020/2021 represents a concerning upward shift after a long period of decline. Globally, TB's status as the deadliest infectious killer was briefly overshadowed by COVID-19 during the pandemic. However, it reclaimed this grim title in 2023. The World Health Organization (WHO) reported that an estimated 10.8 million people contracted TB in 2023, with 1.25 million deaths worldwide, far exceeding the 320,000 COVID-19 deaths officially reported to the WHO in the same year. TB also accounts for more deaths globally than HIV/AIDS and malaria combined. Several factors are attributed to this global and US resurgence. The most prominent is the disruptive impact of the COVID-19 pandemic on healthcare systems worldwide. Pandemic-related lockdowns and strain on medical resources led to significant delays in TB diagnosis, treatment initiation, and public health interventions, resulting in an increased pool of undiagnosed and untreated cases. Experts note that the 'disease rebound' observed post-COVID has allowed other infections, including TB, to resurface. International travel and migration also play a significant role in the US context. A substantial majority (approximately 77%) of TB cases in the US are diagnosed in non-US-born individuals. Consistent with previous years, Mexico, the Philippines, India, and Vietnam were the four most frequently reported countries of birth among non-US-born persons with TB in the United States in 2024. This highlights the global interconnectedness of infectious diseases and the importance of international public health efforts. Furthermore, outbreaks in various US states, such as a notable one in Kansas City in 2024, which saw at least 68 active cases and 91 latent cases, and outbreaks in San Francisco schools, have contributed to the rising numbers. Shortages of primary TB drugs and past cuts to federal funding for TB programs have also been cited as contributing factors to the vulnerability of the public health system. For an Indian audience, this news holds particular relevance. India continues to bear a substantial portion of the global TB burden, accounting for an estimated 26-28% of new global TB cases in 2023, with approximately 2.7-2.8 million new cases. The WHO has acknowledged India's progress in reducing TB incidence (an 18% decline between 2015 and 2023), which is more than double the global decline. However, the country still faces significant challenges, with an estimated 3,23,200 deaths due to TB in 2023. The resurgence of TB in a developed country like the US underscores the persistent global threat of this ancient disease and the critical need for sustained international collaboration, funding, and robust public health infrastructure to achieve global elimination goals. The emergence of drug-resistant strains further complicates treatment and eradication efforts, emphasizing the necessity for early detection and consistent adherence to multi-drug regimens.

Frequently Asked Questions

Read Full Story on Quick Digest